u/Drunken_X

1. Zynquista (sotagliflozin) Type 1 Diabetes NDA Resubmission

Timing: Mid-2026 (company guidance)

This is probably the biggest near-term catalyst. • Lexicon expects to resubmit the NDA for Zynquista in Type 1 Diabetes based on FDA feedback and safety data from the STENO1 study. • Management has stated that a resubmission is anticipated in mid-2026, with the possibility of FDA approval later in 2026 if the required exposure and DKA safety data are achieved. 

Why it matters: A successful resubmission would reopen a large commercial opportunity that investors have largely discounted after prior regulatory setbacks.

⸻

2. SONATA-HCM Phase 3 Enrollment Completion

Timing: Mid-2026

Lexicon’s pivotal SONATA-HCM trial is evaluating sotagliflozin in hypertrophic cardiomyopathy (HCM). • Enrollment of approximately 500 patients is expected to be completed by mid-2026. • The trial is running across roughly 130 sites in 20 countries. 

Why it matters: Completion of enrollment significantly de-risks execution and puts investors on a shorter timeline to the data readout.

⸻

3. SONATA-HCM Topline Data

Timing: Q1 2027

While slightly beyond the next six months, many investors will begin positioning for this event during 2026. • Lexicon continues to guide to Q1 2027 topline results. 

Why it matters: Positive data could create an entirely new indication for sotagliflozin and potentially transform the valuation of the company.

⸻

4. Pilavapadin (LX9211) Partnership Announcement

Timing: Potentially anytime in 2026

Pilavapadin is Lexicon’s non-opioid neuropathic pain candidate. • The FDA End-of-Phase 2 meeting was completed successfully. • Management has repeatedly stated that it is pursuing partnership discussions. 

Why it matters: A licensing deal could bring: • Upfront cash • Development funding • Validation of the program

Given Lexicon’s size, a partnership announcement could be a major stock-moving event.

⸻

5. Novo Nordisk LX9851 Milestones

Timing: Throughout 2026

LX9851 is an oral obesity asset licensed to Novo Nordisk. • Lexicon has already received milestone payments and says it may receive up to an additional $20 million of milestones during 2026.  • Novo initiated Phase 1 development in 2026. 

Why it matters: These are non-dilutive cash inflows and help fund operations without equity issuance.

⸻

6. International Sotagliflozin Approvals

Timing: Throughout 2026

Viatris is responsible for commercialization outside the U.S. and Europe. • Regulatory filings have been submitted in markets including Canada, Australia, and New Zealand. • Lexicon expects additional approvals and submissions during 2026. 

Why it matters: Each approval further validates the asset and may generate commercial or milestone revenue.

1. Zynquista (sotagliflozin) Type 1 Diabetes NDA Resubmission

Timing: Mid-2026 (company guidance)

This is probably the biggest near-term catalyst. • Lexicon expects to resubmit the NDA for Zynquista in Type 1 Diabetes based on FDA feedback and safety data from the STENO1 study. • Management has stated that a resubmission is anticipated in mid-2026, with the possibility of FDA approval later in 2026 if the required exposure and DKA safety data are achieved. 

Why it matters: A successful resubmission would reopen a large commercial opportunity that investors have largely discounted after prior regulatory setbacks.

⸻

2. SONATA-HCM Phase 3 Enrollment Completion

Timing: Mid-2026

Lexicon’s pivotal SONATA-HCM trial is evaluating sotagliflozin in hypertrophic cardiomyopathy (HCM). • Enrollment of approximately 500 patients is expected to be completed by mid-2026. • The trial is running across roughly 130 sites in 20 countries. 

Why it matters: Completion of enrollment significantly de-risks execution and puts investors on a shorter timeline to the data readout.

⸻

3. SONATA-HCM Topline Data

Timing: Q1 2027

While slightly beyond the next six months, many investors will begin positioning for this event during 2026. • Lexicon continues to guide to Q1 2027 topline results. 

Why it matters: Positive data could create an entirely new indication for sotagliflozin and potentially transform the valuation of the company.

⸻

4. Pilavapadin (LX9211) Partnership Announcement

Timing: Potentially anytime in 2026

Pilavapadin is Lexicon’s non-opioid neuropathic pain candidate. • The FDA End-of-Phase 2 meeting was completed successfully. • Management has repeatedly stated that it is pursuing partnership discussions. 

Why it matters: A licensing deal could bring: • Upfront cash • Development funding • Validation of the program

Given Lexicon’s size, a partnership announcement could be a major stock-moving event.

⸻

5. Novo Nordisk LX9851 Milestones

Timing: Throughout 2026

LX9851 is an oral obesity asset licensed to Novo Nordisk. • Lexicon has already received milestone payments and says it may receive up to an additional $20 million of milestones during 2026.  • Novo initiated Phase 1 development in 2026. 

Why it matters: These are non-dilutive cash inflows and help fund operations without equity issuance.

⸻

6. International Sotagliflozin Approvals

Timing: Throughout 2026

Viatris is responsible for commercialization outside the U.S. and Europe. • Regulatory filings have been submitted in markets including Canada, Australia, and New Zealand. • Lexicon expects additional approvals and submissions during 2026. 

Why it matters: Each approval further validates the asset and may generate commercial or milestone revenue.